Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
July 30, 2021 08:00 ET
|
Optinose, Inc.
Company Expects Top-Line Results in First Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
July 28, 2021 08:00 ET
|
Optinose, Inc.
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020 Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million Conference Call and...
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
June 24, 2021 08:00 ET
|
Optinose, Inc.
YARDLEY, Pa., June 24, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
May 05, 2021 07:00 ET
|
Optinose, Inc.
Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be...
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
April 28, 2021 08:30 ET
|
Optinose, Inc.
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...
Optinose to Present at the Needham Virtual Healthcare Conference
April 12, 2021 16:15 ET
|
Optinose, Inc.
YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
March 03, 2021 07:00 ET
|
Optinose, Inc.
Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company...
Optinose to Highlight Data at Two Upcoming Scientific Meetings
October 03, 2018 07:00 ET
|
OptiNose, Inc.
YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
July 02, 2018 17:11 ET
|
OptiNose, Inc.
YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Pricing of Public Offering of Common Stock
June 06, 2018 20:21 ET
|
OptiNose, Inc.
YARDLEY, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public...